177 related articles for article (PubMed ID: 34609407)
1. HOXB13 and TFF3 can contribute to the prognostic stratification of prostate adenocarcinoma.
Timofte AD; Giuşcă SE; Lozneanu L; Manole MB; Prutianu I; Gafton B; Rusu A; Căruntu ID
Rom J Morphol Embryol; 2021; 62(1):41-52. PubMed ID: 34609407
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Evaluation of TFF3 Promoter Hypomethylation and Molecular Biomarker Potential for Prostate Cancer Diagnosis and Prognosis.
Nørgaard M; Haldrup C; Storebjerg TM; Vestergaard EM; Wild PJ; Høyer S; Borre M; Ørntoft TF; Sørensen KD
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28930171
[TBL] [Abstract][Full Text] [Related]
3. Renal Function Parameters in Distinctive Molecular Subtypes of Prostate Cancer.
Timofte AD; Caruntu ID; Covic AC; Hancianu M; Girlescu N; Chifu MB; Giusca SE
Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894380
[TBL] [Abstract][Full Text] [Related]
4. HOXB13 overexpression is an independent predictor of early PSA recurrence in prostate cancer treated by radical prostatectomy.
Zabalza CV; Adam M; Burdelski C; Wilczak W; Wittmer C; Kraft S; Krech T; Steurer S; Koop C; Hube-Magg C; Graefen M; Heinzer H; Minner S; Simon R; Sauter G; Schlomm T; Tsourlakis MC
Oncotarget; 2015 May; 6(14):12822-34. PubMed ID: 25825985
[TBL] [Abstract][Full Text] [Related]
5. HOXB13 as an immunohistochemical marker of prostatic origin in metastatic tumors.
Barresi V; Ieni A; Cardia R; Licata L; Vitarelli E; Reggiani Bonetti L; Tuccari G
APMIS; 2016 Mar; 124(3):188-93. PubMed ID: 26590121
[TBL] [Abstract][Full Text] [Related]
6. Clinical value of ERG, TFF3, and SPINK1 for molecular subtyping of prostate cancer.
Terry S; Nicolaiew N; Basset V; Semprez F; Soyeux P; Maillé P; Vacherot F; Ploussard G; Londoño-Vallejo A; de la Taille A; Allory Y
Cancer; 2015 May; 121(9):1422-30. PubMed ID: 25639219
[TBL] [Abstract][Full Text] [Related]
7. Somatic HOXB13 Expression Correlates with Metastatic Progression in Men with Localized Prostate Cancer Following Radical Prostatectomy.
Weiner AB; Faisal FA; Davicioni E; Karnes RJ; Griend DJV; Lotan TL; Schaeffer EM
Eur Urol Oncol; 2021 Dec; 4(6):955-962. PubMed ID: 32540218
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of HOXB13 as a molecular marker of recurrent prostate cancer.
Jeong TO; Oh KJ; Xuan Nguyen NT; Kim YR; Kim MS; Lee SD; Ryu SB; Jung C
Mol Med Rep; 2012 Apr; 5(4):901-4. PubMed ID: 22293681
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity of HOXB13 as a Diagnostic Immunohistochemical Marker of Prostatic Origin in Prostate Cancer Metastases: Comparison to PSA, Prostein, Androgen Receptor, ERG, NKX3.1, PSAP, and PSMA.
Kristiansen I; Stephan C; Jung K; Dietel M; Rieger A; Tolkach Y; Kristiansen G
Int J Mol Sci; 2017 May; 18(6):. PubMed ID: 28555048
[TBL] [Abstract][Full Text] [Related]
10. Combined loss of TFF3 and PTEN is associated with lethal outcome and overall survival in men with prostate cancer.
Abou-Ouf H; Ghosh S; Box A; Palanisamy N; Bismar TA
J Cancer Res Clin Oncol; 2019 Jul; 145(7):1751-1759. PubMed ID: 31129769
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of the HOXB13 G84E mutation in Danish men undergoing radical prostatectomy and its correlations with prostate cancer risk and aggressiveness.
Storebjerg TM; Høyer S; Kirkegaard P; Bro F; ; Ørntoft TF; Borre M; Sørensen KD
BJU Int; 2016 Oct; 118(4):646-53. PubMed ID: 26779768
[TBL] [Abstract][Full Text] [Related]
12. V-ets erythroblastosis virus E26 oncogene homolog (avian)/Trefoil factor 3/high-molecular-weight cytokeratin triple immunostain: a novel tissue-based biomarker in prostate cancer with potential clinical application.
Park K; Chiu YL; Rubin MA; Demichelis F; Mosquera JM
Hum Pathol; 2013 Oct; 44(10):2282-92. PubMed ID: 23856515
[TBL] [Abstract][Full Text] [Related]
13. Plasma levels of trefoil factors are increased in patients with advanced prostate cancer.
Vestergaard EM; Borre M; Poulsen SS; Nexø E; Tørring N
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):807-12. PubMed ID: 16467092
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of the HOXB13 G84E germline mutation in British men and correlation with prostate cancer risk, tumour characteristics and clinical outcomes.
Kote-Jarai Z; Mikropoulos C; Leongamornlert DA; Dadaev T; Tymrakiewicz M; Saunders EJ; Jones M; Jugurnauth-Little S; Govindasami K; Guy M; Hamdy FC; Donovan JL; Neal DE; Lane JA; Dearnaley D; Wilkinson RA; Sawyer EJ; Morgan A; Antoniou AC; Eeles RA;
Ann Oncol; 2015 Apr; 26(4):756-761. PubMed ID: 25595936
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Value of Trefoil Factor 3 Expression in Patients with Gastric Cancer.
Taniguchi Y; Kurokawa Y; Takahashi T; Mikami J; Miyazaki Y; Tanaka K; Makino T; Yamasaki M; Nakajima K; Mori M; Doki Y
World J Surg; 2018 Dec; 42(12):3997-4004. PubMed ID: 30039286
[TBL] [Abstract][Full Text] [Related]
16. [Gleason score 8-10 prostatic adenocarcinoma: prognostic influence in the biochemical progression free survival].
Rioja Zuazu J; Zudaire Berbera JJ; Rincón Mayans A; Rosell Costa D; Robles Garcia JE; Berian Polo JM
Actas Urol Esp; 2008 Sep; 32(8):792-8. PubMed ID: 19013977
[TBL] [Abstract][Full Text] [Related]
17. Clinical and pathological significance of the level and extent of capsular invasion in clinical stage T1-2 prostate cancer.
Wheeler TM; Dillioglugil O; Kattan MW; Arakawa A; Soh S; Suyama K; Ohori M; Scardino PT
Hum Pathol; 1998 Aug; 29(8):856-62. PubMed ID: 9712429
[TBL] [Abstract][Full Text] [Related]
18. The prognostic nomogram for PSA-incongruent low-risk prostate cancer treated by radical prostatectomy.
Wang Y; Zhu Y; Fan L; Liu J; Pan J; Xue W
Int Urol Nephrol; 2023 Jun; 55(6):1447-1452. PubMed ID: 37017821
[TBL] [Abstract][Full Text] [Related]
19. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
[TBL] [Abstract][Full Text] [Related]
20. Tertiary Gleason pattern 5 is a powerful predictor of biochemical relapse in patients with Gleason score 7 prostatic adenocarcinoma.
Hattab EM; Koch MO; Eble JN; Lin H; Cheng L
J Urol; 2006 May; 175(5):1695-9; discussion 1699. PubMed ID: 16600733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
